Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
10
02
2020
revised:
24
03
2020
accepted:
24
04
2020
pubmed:
7
5
2020
medline:
31
8
2021
entrez:
7
5
2020
Statut:
ppublish
Résumé
To date, various chemically synthesized and biosynthesized nanoparticles, or hybrid nanosystems and/or nanoplatforms, have been developed under the umbrella of nanomedicine. These can be introduced into the body orally, nasally, intratumorally or intravenously. Successfully translating hybrid nanoplatforms from preclinical proof-of-concept to therapeutic value in the clinic is challenging. Having made significant advances with drug delivery technologies, we must learn from other areas of oncology drug development, where patient stratification and target-driven design have improved patient outcomes. This review aims to identify gaps in our understanding of the current strengths of nanomedicine platforms in drug delivery and cancer theranostics. We report on the current approaches of nanomedicine at preclinical and clinical stages.
Identifiants
pubmed: 32371139
pii: S1359-6446(20)30166-5
doi: 10.1016/j.drudis.2020.04.018
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1245-1252Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.